FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* MILLIGAN DAVID V				<u>M</u>	2. Issuer Name and Ticker or Trading Symbol MADRIGAL PHARMACEUTICALS, INC. [MDGL]								5. Relationship of Reportir (Check all applicable) X Director			g Per	10% O	wner
(Last)	(Fi	rst)	Middle)		-									Officer below)	(give title		Other (below)	specify
C/O MADRIGAL PHARMACEUTICALS, INC. 200 BARR HARBOR DRIVE, SUITE 400					3. Date of Earliest Transaction (Month/Day/Year) 06/17/2020													
(Street) WEST CONSHOHOCKEN PA 19428				4. I	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Indiv Line) X	· ·						
(City)	(SI	ate)	(Zip)															
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					Execution Date,			Code (II					and Securitie Benefici		es Formally (D) of Following (I) (II)		m: Direct or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
								Code	v	Amount	(A) or (D) Prid		e	Transaction(s) (Instr. 3 and 4)				(11301.4)
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		n of l		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		De Se (Ir	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amous or Number of Shares	er					
Stock Option (Right to buy)	\$111.06	06/17/2020		A		6,000		(1)	0	6/17/2025	Common Stock	6,00	0	\$0.00	6,000		D	

Explanation of Responses:

1. The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date.

Remarks:

/s/ Brian Lynch, as attorney-infact for David Milligan, M.D. 06/17/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.